Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Melanoma Res ; 29(5): 527-532, 2019 10.
Article in English | MEDLINE | ID: mdl-31095039

ABSTRACT

Given the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of patients who received dabrafenib in a compassionate use setting through the Named Patient Program (DESCRIBE I study) during December 2010-August 2013 in Europe, New Zealand and Australia. Of the 331 Named Patient Program patients included, the majority (95.8%) had stage IV disease at dabrafenib initiation and 39.9% had brain metastases (BMs). Dabrafenib was used first line in 67.7% of patients, and median treatment duration was 6.4 months. Dabrafenib was well tolerated. Common grade 2/3 adverse events were hyperkeratosis (7.6%), pyrexia/fever (6.6%), fatigue (5.1%), hand-foot syndrome (5.4%) and nausea (3.6%). Overall response rate was 45.9%, median progression-free survival was 5.2 months (95% confidence interval, 4.2-6.1 months), and median overall survival was 12.4 months (95% confidence interval, 10.2-15.0 months). In patients with known brain metastases (n = 132) versus patients without (n = 199), overall response rate was 42.4% versus 48.2%, progression-free survival was 3.9 months (95% confidence interval, 3.8-5.5 months) versus 5.9 months (95% confidence interval, 4.8-7.8 months) and overall survival was 9.5 months (95% confidence interval, 6.7-12.4 months) versus 15 months (95% confidence interval, 11.1-20.5 months), respectively. Safety and effectiveness of dabrafenib in patients with unresectable advanced BRAF V600-mutant melanoma treated in an Named Patient Program was similar to the clinical trial experience, demonstrating effectiveness of dabrafenib in a nontrial setting.


Subject(s)
Imidazoles/therapeutic use , Melanoma/drug therapy , Melanoma/genetics , Oximes/therapeutic use , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Brain Neoplasms/secondary , Compassionate Use Trials , Disease-Free Survival , Female , Humans , Lymphatic Metastasis , Male , Middle Aged , Mutation , Neoplasm Metastasis , Patient Safety , Retrospective Studies , Treatment Outcome , Young Adult
2.
Pharmaceut Med ; 33(2): 121-133, 2019 04.
Article in English | MEDLINE | ID: mdl-31933256

ABSTRACT

BACKGROUND: Voriconazole is an extended-spectrum antifungal agent approved for the treatment and prophylaxis of invasive aspergillosis and other serious fungal infections. In 2014, additional risk minimization measures (aRMM) consisting of a Healthcare Professional (HCP) Question and Answer (Q&A) Brochure, HCP Checklist, and Patient Alert Card were implemented on a rolling basis across the European Union (EU) to mitigate three key risks with voriconazole: phototoxicity, squamous cell carcinoma (SCC) of the skin, and hepatotoxicity. The risks of phototoxicity and hepatotoxicity have been documented in the Summary of Product Characteristics (SmPC) since voriconazole was first approved in the EU in 2002. However, the risk of SCC of the skin was a more recent addition to the SmPC (added in 2010). OBJECTIVES: We evaluated the effectiveness of the aRMM, as per EU Good Pharmacovigilance Practices Module XVI, via a survey of HCPs. METHODS: An online survey was conducted among specialty care HCPs in 10 EU countries who had received by mail aRMM tools 12 months previously. Survey questions evaluated HCPs' receipt and utilization of aRMM tools, and knowledge of the three risks. RESULTS: Of 27,396 HCPs invited to participate, 332 eligible respondents completed the survey (response rate: 447/26,735; 1.7%). In total, 19.6% of respondents recalled receiving the HCP Q&A Brochure, 22.6% the HCP Checklist, and 25.9% the Patient Alert Card. HCPs had a high level of knowledge of phototoxicity and hepatotoxicity; however, knowledge of SCC was lower. Knowledge of the three risks and self-reported risk minimization behavior was slightly improved in those who had read the HCP Q&A Brochure compared with those who had not. CONCLUSION: The effectiveness of the voriconazole aRMM cannot be meaningfully inferred from the results due to the low survey response rate. The assessment indirectly points to the SmPC or other resources being the main source of risk information for HCPs. Engaging HCPs before designing and implementing an aRMM program is crucial to ensure an effective and focused program. (EU PAS registration number: EUPAS12624).


Subject(s)
Antifungal Agents/adverse effects , European Union/organization & administration , Health Personnel/statistics & numerical data , Voriconazole/adverse effects , Antifungal Agents/therapeutic use , Carcinoma, Squamous Cell/chemically induced , Checklist , Chemical and Drug Induced Liver Injury , Cross-Sectional Studies , Dermatitis, Phototoxic/complications , Drug-Related Side Effects and Adverse Reactions , Health Care Surveys/methods , Humans , Invasive Pulmonary Aspergillosis/drug therapy , Mycoses/drug therapy , Pamphlets , Pharmacovigilance , Risk Reduction Behavior , Self Report , Skin Neoplasms/pathology , Voriconazole/therapeutic use
3.
Cancer ; 124(11): 2407-2414, 2018 06 01.
Article in English | MEDLINE | ID: mdl-29579334

ABSTRACT

BACKGROUND: This is the first report of long-term (>10 years) safety, tolerability, and survival data on patients with non-small cell lung cancer (NSCLC) who received treatment with gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. METHODS: Patients with advanced NSCLC (N = 191) who entered the IRESSA Clinical Access Program (ICAP) (June 2011 to January 2013) and had previously obtained a clinical benefit from gefitinib therapy (including patients who had received gefitinib since 2001) were analyzed for adverse events (AEs). A subset of patients (n = 79) underwent retrospective chart review to capture demographic, safety, and survival data. RESULTS: Seventy-five of 191 patients (39%) remained on long-term gefitinib therapy as of September 2016. Overall, serious AEs (SAEs) were reported in 64 patients (34%), the majority of which were attributed to underlying disease or comorbidities; only 3 patients (1.6%) had SAEs that were considered as possibly gefitinib-related. In the retrospective chart review cohort, 70% of patients were women; 58% were former smokers, and 30% were never-smokers; 56% were diagnosed with adenocarcinoma, and 13% were diagnosed with squamous carcinoma. Although EGFR mutational status was tested in only 17 patients (22%), it was assumed that most tumors were EGFR-mutation-positive. The median duration of gefitinib therapy was 11.1 years (7.8 years before and 3.5 years during ICAP), with 10-year and 15-year survival rates of 86% and 59%, respectively, from the initiation of therapy. CONCLUSIONS: A subset of long-term NSCLC survivors who were receiving gefitinib had an excellent long-term safety profile. Although it is assumed that most of these patients' tumors harbor EGFR mutations, molecular studies of available tumor specimens are planned to uncover the features that predict long-term survival. Cancer 2018;124:2407-14. © 2018 American Cancer Society.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Non-Small-Cell Lung/drug therapy , Gefitinib/administration & dosage , Lung Neoplasms/drug therapy , Protein Kinase Inhibitors/administration & dosage , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Disease-Free Survival , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/genetics , Female , Gefitinib/adverse effects , Humans , Lung Neoplasms/genetics , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Mutation , Prospective Studies , Protein Kinase Inhibitors/adverse effects , Retrospective Studies , Survival Analysis , Survival Rate , Time Factors , United States/epidemiology , Young Adult
4.
Acta Oncol ; 56(12): 1769-1775, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28723233

ABSTRACT

BACKGROUND: A named patient program (NPP) was designed to provide patients with advanced soft-tissue sarcoma (aSTS) access to pazopanib, a multitargeted tyrosine kinase inhibitor. The SPIRE study was a retrospective chart review of participating patients. PATIENTS AND METHODS: Eligibility criteria for the NPP and SPIRE mirrored those of the pivotal phase-III study, PALETTE, which compared pazopanib with placebo in patients ≥18 years with aSTS and whose disease had progressed during or following prior chemotherapy or were otherwise unsuitable for chemotherapy. Outcomes of interest included treatment patterns, treatment duration, relative dose intensity, progression-free survival (PFS), overall survival (OS), clinical benefit rate, adverse events (AEs) and reasons for treatment discontinuation. RESULTS: A total of 211 patients were enrolled (median age 56 years; 60% female). Most patients received pazopanib in second- and third-line therapy (28.0% and 28.4%, respectively), followed by fourth line (19.0%) and ≥ fifth line (18.5%). The median duration of pazopanib treatment was 3.1 months (95% CI: 2.8-3.8), with a mean daily dose of 715 mg equating to 92% of recommended dose. Median OS was 11.1 months and clinical benefit rate was 46%. There was evidence of some clinical benefit across most histological subtypes. At study end, 40% of patients were alive and of these, 18% remained on pazopanib. Thirteen percent (13%) of patients discontinued pazopanib due to AEs. CONCLUSIONS: The SPIRE study demonstrated activity of pazopanib in heavily pretreated aSTS patients in a compassionate use setting. No new safety concerns were noted. Reassuringly, the relative dose intensity of pazopanib was 92%.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Pyrimidines/therapeutic use , Sarcoma/drug therapy , Sulfonamides/therapeutic use , Compassionate Use Trials , Disease-Free Survival , Female , Hemangiosarcoma/drug therapy , Hemangiosarcoma/pathology , Humans , Indazoles , Leiomyosarcoma/drug therapy , Leiomyosarcoma/pathology , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Male , Middle Aged , Retrospective Studies , Sarcoma/pathology , Sarcoma, Synovial/drug therapy , Sarcoma, Synovial/pathology , Solitary Fibrous Tumors/drug therapy , Solitary Fibrous Tumors/pathology , Survival Rate , Time Factors , Uterine Neoplasms/drug therapy , Uterine Neoplasms/pathology
5.
J Dtsch Dermatol Ges ; 10(10): 727-32, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22577946

ABSTRACT

BACKGROUND: Rituximab has been reported to be effective in various small case series of patients with severe and/or refractory pemphigus. However, no systematic evaluation is available to corroborate this observation. The aim of this study was to systematically determine efficacy and safety of rituximab in treatment-resistant pemphigus. PATIENTS AND METHODS: Multicenter retrospective, observational study of 36 patients with severe pemphigus vulgaris (n = 33) and pemphigus foliaceus (n = 3) treated with rituximab before August 31(st) , 2008 and enrolled in a national observational registery between December 2008 and June 2009. RESULTS: Within a mean period of observation of 11 (1-37) months, 21 (58 %) pemphigus patients showed complete, 13 (36 %) partial, and 2 (6 %) no response to rituximab treatment. This correlates with a mean improvement of the visual analog scale for well-being of 34 (20-60) at baseline to 75 (40-95) at the last control visit. In 4 (11 %) patients, severe adverse events were recorded including 1 (3 %) serious infection. CONCLUSIONS: Data collected in this systematic registry indicate that rituximab is an effective and relatively safe adjuvant treatment option for refractory pemphigus. To further extend our knowledge on efficacy and safety of this drug, controlled prospective trials are required.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/adverse effects , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Drug-Related Side Effects and Adverse Reactions/epidemiology , Pemphigus/drug therapy , Pemphigus/epidemiology , Registries , Adolescent , Adult , Aged , Comorbidity , Female , Germany/epidemiology , Humans , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , Male , Middle Aged , Prevalence , Risk Factors , Rituximab , Treatment Outcome , Young Adult
6.
Intensive Care Med ; 35(11): 1868-76, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19652948

ABSTRACT

RATIONALE: Use of etomidate in the critically ill is controversial due to its links with an inadequate response to corticotropin and potential for excess mortality. In a septic shock population, we tested the hypotheses that etomidate administration induces more non-responders to corticotropin and increases mortality and that hydrocortisone treatment decreases mortality in patients receiving etomidate. METHODS: An a-priori sub-study of the CORTICUS multi-centre, randomised, double-blind, placebo-controlled trial of hydrocortisone in septic shock. Use and timing of etomidate administration were collected. Endpoints were corticotropin response and all-cause 28-day mortality in patients receiving etomidate. MEASUREMENTS AND MAIN RESULTS: Five hundred patients were recruited, of whom 499 were analysable; 96 (19.2%) were administered etomidate within the 72 h prior to inclusion. The proportion of non-responders to corticotropin was significantly higher in patients who were given etomidate in the 72 h before trial inclusion than in other patients (61.0 vs. 44.6%, P = 0.004). Etomidate therapy was associated with a higher 28-day mortality in univariate analysis (P = 0.02) and after correction for severity of illness (42.7 vs. 30.5%; P = 0.06 and P = 0.03) in our two multi-variant models. Hydrocortisone administration did not change the mortality of patients receiving etomidate (45 vs. 40%). CONCLUSIONS: The use of bolus dose etomidate in the 72 h before study inclusion is associated with an increased incidence of inadequate response to corticotropin, but is also likely to be associated with an increase in mortality. We recommend clinicians demonstrate extreme caution in the use of etomidate in critically ill patients with septic shock.


Subject(s)
Adrenocorticotropic Hormone , Etomidate/adverse effects , Hypnotics and Sedatives/adverse effects , Shock, Septic/drug therapy , Shock, Septic/mortality , Adrenal Glands/drug effects , Adrenocorticotropic Hormone/blood , Adrenocorticotropic Hormone/drug effects , Aged , Analysis of Variance , Anti-Inflammatory Agents/therapeutic use , Cause of Death , Critical Care/methods , Double-Blind Method , Drug Antagonism , Europe/epidemiology , Female , Humans , Hydrocortisone/analogs & derivatives , Hydrocortisone/therapeutic use , Kaplan-Meier Estimate , Logistic Models , Male , Middle Aged , Multivariate Analysis , Patient Selection , Prospective Studies , Severity of Illness Index , Shock, Septic/blood , Statistics, Nonparametric , Treatment Failure
7.
Clin Res Cardiol ; 97(11): 836-42, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18648724

ABSTRACT

Sleep disordered breathing (SDB) has a high prevalence and prognostic impact in patients with chronic heart failure (CHF). Aim of this study was to investigate variability of SDB parameters in patients with stable CHF. Cardiorespiratory polygraphy was used to determine SDB in two consecutive nights in 50 CHF patients (NYHA class > or = II, LV-EF < or = 40%). The apnea-hypopnea-index (AHI) and apnoea-index (AI) were used to quantify SDB severity. Central, obstructive or mixed SDB were classified according to the majority of events. There was an excellent correlation in AHI (r = 0.948, P < 0.001) and AI (r = 0.842, P < 0.001) results of both nights. The overall number of detected apnea and hypopnea during the first night as compared to the maximum of both nights was 85% for the AHI and 77% for the AI. The reproducibility was dependent on SDB severity: AHI 15-29/h = 87%, AHI > or = 30/h = 92% and AI > or = 10/h = 83%. Classification was identical in 17 out of 19 patients with AI > or = 10/h. In patients with stable CHF a single night of cardiorespiratory monitoring leads to representative results on severity and type of SDB. This may enhance the applicability and dissemination of cardiorespiratory polygraphy in clinical practice.


Subject(s)
Heart Failure/complications , Heart Failure/physiopathology , Polysomnography/methods , Sleep Apnea Syndromes/complications , Sleep Apnea Syndromes/physiopathology , Aged , Female , Germany/epidemiology , Heart Failure/epidemiology , Humans , Male , Middle Aged , Prevalence , Prospective Studies , Reproducibility of Results , Severity of Illness Index , Sleep Apnea Syndromes/epidemiology , Sleep Apnea, Central/complications , Sleep Apnea, Central/physiopathology , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/physiopathology
8.
N Engl J Med ; 358(2): 111-24, 2008 Jan 10.
Article in English | MEDLINE | ID: mdl-18184957

ABSTRACT

BACKGROUND: Hydrocortisone is widely used in patients with septic shock even though a survival benefit has been reported only in patients who remained hypotensive after fluid and vasopressor resuscitation and whose plasma cortisol levels did not rise appropriately after the administration of corticotropin. METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 251 patients to receive 50 mg of intravenous hydrocortisone and 248 patients to receive placebo every 6 hours for 5 days; the dose was then tapered during a 6-day period. At 28 days, the primary outcome was death among patients who did not have a response to a corticotropin test. RESULTS: Of the 499 patients in the study, 233 (46.7%) did not have a response to corticotropin (125 in the hydrocortisone group and 108 in the placebo group). At 28 days, there was no significant difference in mortality between patients in the two study groups who did not have a response to corticotropin (39.2% in the hydrocortisone group and 36.1% in the placebo group, P=0.69) or between those who had a response to corticotropin (28.8% in the hydrocortisone group and 28.7% in the placebo group, P=1.00). At 28 days, 86 of 251 patients in the hydrocortisone group (34.3%) and 78 of 248 patients in the placebo group (31.5%) had died (P=0.51). In the hydrocortisone group, shock was reversed more quickly than in the placebo group. However, there were more episodes of superinfection, including new sepsis and septic shock. CONCLUSIONS: Hydrocortisone did not improve survival or reversal of shock in patients with septic shock, either overall or in patients who did not have a response to corticotropin, although hydrocortisone hastened reversal of shock in patients in whom shock was reversed. (ClinicalTrials.gov number, NCT00147004.)


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Hydrocortisone/therapeutic use , Shock, Septic/drug therapy , Adrenal Glands/drug effects , Adrenal Glands/metabolism , Adrenocorticotropic Hormone/pharmacology , Adult , Aged , Anesthetics, Intravenous/pharmacology , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/metabolism , Double-Blind Method , Drug Therapy, Combination , Etomidate/pharmacology , Female , Hormones/pharmacology , Humans , Hydrocortisone/adverse effects , Hydrocortisone/metabolism , Injections, Intravenous , Kaplan-Meier Estimate , Male , Middle Aged , Shock, Septic/microbiology , Shock, Septic/mortality , Treatment Failure
9.
Scand J Gastroenterol ; 42(2): 247-55, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17327945

ABSTRACT

OBJECTIVE: Patient- and virus-related factors influence the response of patients with chronic hepatitis C to interferon-based therapy. The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors. MATERIAL AND METHODS: We combined data from two randomized, multinational trials in which patients received peginterferon alfa-2a (40KD) plus ribavirin. The logistic regression model for patients infected with hepatitis C virus genotype 1 included age, viral load, histology, alanine aminotransferase quotient, body mass index, treatment duration, ribavirin dose and adherence. RESULTS: In the genotype 1 model, varying baseline factors had a striking effect on the probability of sustained virological response. A dramatic difference in the probability of sustained virological response was seen in a series of hypothetical patients in whom five factors were varied to represent best and worst case scenarios. The best case scenario (age 20 years; no cirrhosis/bridging fibrosis; alanine aminotransferase quotient=7; body mass index 20 kg/m2; viral load 40,000 IU/mL) was associated with a 97% probability of sustained virological response, compared with 7% in the worst case scenario (age 60 years; cirrhosis/bridging fibrosis; alanine aminotransferase quotient=1; body mass index 30 kg/m2; viral load 9,000,000 IU/mL). Both adherence to treatment and achieving an early virological response increased the probability of sustained virological response. CONCLUSIONS: In treatment-naïve patients with chronic hepatitis C, host factors play a major role in determining treatment outcome and the logistic regression model is useful for predicting the probability of sustained virological response in individual patients.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepatitis C, Chronic/virology , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Adolescent , Adult , Drug Carriers , Drug Therapy, Combination , Genotype , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C Antibodies/analysis , Hepatitis C, Chronic/drug therapy , Humans , Interferon alpha-2 , Middle Aged , RNA, Viral/analysis , Recombinant Proteins , Treatment Outcome
10.
Nutr Cancer ; 46(2): 131-7, 2003.
Article in English | MEDLINE | ID: mdl-14690788

ABSTRACT

In 1998-2000, a case-control study of breast cancer was conducted in Heidelberg, Germany. Three hundred ten consecutively recruited cases with primary breast cancer were matched according to 10-yr age groups to 353 controls with conditions unrelated to diet or endocrine disorders. Intake of raw vegetables, total vegetables, and whole-grain products was inversely associated with breast cancer risk (highest vs. lowest quartile adjusted odds ratio [OR] 0.51, 95% confidence interval [CI] 0.31-0.84; OR = 0.62, 95% CI = 0.38-1.02; and OR = 0.57; 95% CI = 0.34-0.95, respectively). Also, high intake of some selected vitamins and minerals possessing putative DNA-stabilizing properties displayed significant inverse risk associations. Adjusted ORs were as follows: vitamin C (OR = 0.49, 95% CI = 0.2-0.88), folate equivalents (OR = 0.47, 95% CI = 0.25-0.88), b-carotene (OR = 0.46, 95% CI = 0.27-0.80), zinc (OR = 0.35, 95% CI = 0.15-0.78), and copper (OR = 0.51, 95% CI = 0.31-1.03). In contrast, no significant association with risk was seen for an increased intake of fruits, cooked vegetables, fiber, calcium, manganese, or iron. In this population of German women, components of raw vegetables and some micronutrients appear to decrease breast cancer risk.


Subject(s)
Breast Neoplasms/epidemiology , Diet , Fruit , Micronutrients/administration & dosage , Vegetables , Adult , Aged , Ascorbic Acid/administration & dosage , Breast Diseases/epidemiology , Case-Control Studies , Copper/administration & dosage , DNA/metabolism , Dietary Fiber/administration & dosage , Drug Stability , Edible Grain , Female , Folic Acid/administration & dosage , Germany/epidemiology , Hot Temperature , Humans , Middle Aged , Odds Ratio , Risk Factors , Zinc/administration & dosage , beta Carotene/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...